Neoadjuvant PD-1 Inhibitor Sequencing Before Tumor Resection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-small cell lung cancer (NSCLC), liver cancer (particularly hepatocellular carcinoma, HCC), and head and neck squamous cell carcinoma (HNSCC) are inadequate, with high recurrence rates and limited survival benefits, especially in early-stage and operable cases, necessitating improved therapeutic approaches.
Innovation Solution
Administering a programmed death-1 (PD-1) inhibitor, such as cemiplimab, as neoadjuvant therapy followed by surgical resection, and optionally as adjuvant therapy, to target PD-1 and potentially reduce tumor burden and recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (chemotherapy, surgery alone) are used for NSCLC, HCC, and HNSCC, then treatment can be administered with current standard protocols, but tumor recurrence rates remain high and survival benefits are limited
Solution Approach 1:
The patent applies neoadjuvant PD-1 inhibitor therapy before surgical resection to shrink tumors and eliminate micrometastases early in the treatment course. This preliminary immunotherapeutic action primes the immune system to recognize and attack tumor cells, leading to reduced recurrence rates and improved survival outcomes compared to surgery alone or conventional chemotherapy approaches.
2Quantity of substance
If PD-1/PD-L1 blockade is combined with chemotherapy, then some tumor response may be achieved, but the majority of patients do not achieve significant clinical benefit
Solution Approach 1:
The patent extracts and isolates the most effective therapeutic approach by using PD-1 inhibitor monotherapy rather than combining it with chemotherapy. This eliminates the toxicities and reduced efficacy associated with combination therapy, demonstrating that PD-1 blockade alone achieves superior clinical benefit rates while maintaining tumor burden reduction.
3Ease of manufacture
If surgery is performed alone for early-stage NSCLC, HCC, and HNSCC, then tumor can be removed, but recurrence occurs in the majority of patients due to residual micrometastases
Solution Approach 1:
The patent introduces PD-1 inhibitors as an intermediary immunotherapeutic agent between surgery and adjuvant treatment. This mediator activates the patient's own immune system to target and eliminate residual micrometastases that surgery cannot remove, thereby extending disease-free survival while maintaining the simplicity of surgical resection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method leads to significant tumor necrosis, regression, and reduced recurrence, extending disease-free and overall survival in patients with liver, lung, and head and neck cancers.
Implementation Method 1
Administering a programmed death-1 (PD-1) inhibitor, such as cemiplimab, as neoadjuvant therapy followed by surgical resection, and optionally as adjuvant therapy, to target PD-1
Data Source
AI summary
The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or abioequivalent thereof) as neoadjuvant therapy followed by surgical resection and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the liver cancer is hepatocellular carcinoma (HCC), the lung cancer is non-small cell lung cancer (NSCLC), or the head and neck cancer is head and neck squamous cell carcinoma (HNSCC).